0001567619-19-019555.txt : 20191015 0001567619-19-019555.hdr.sgml : 20191015 20191015150852 ACCESSION NUMBER: 0001567619-19-019555 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20191015 DATE AS OF CHANGE: 20191015 EFFECTIVENESS DATE: 20191015 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Elicio Therapeutics, Inc. CENTRAL INDEX KEY: 0001555192 IRS NUMBER: 452966790 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-351051 FILM NUMBER: 191150789 BUSINESS ADDRESS: STREET 1: ONE KENDALL SQUARE STREET 2: BUILDING 1400 WEST, SUITE 14303 CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 1-339-206-0793 MAIL ADDRESS: STREET 1: ONE KENDALL SQUARE STREET 2: BUILDING 1400 WEST, SUITE 14303 CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: Vedantra Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20120730 D 1 primary_doc.xml X0708 D LIVE 0001555192 Elicio Therapeutics, Inc. ONE KENDALL SQUARE BUILDING 1400 WEST, SUITE 14303 CAMBRIDGE MA MASSACHUSETTS 02139 617-360-9995 DELAWARE None Vedantra Pharmaceuticals, Inc. Corporation true Daniel Geffken c/o Elicio, One Kendall Sq. Bldg. 1400 West, Suite 14303 Cambridge MA MASSACHUSETTS 02139 Executive Officer Director Mr. Geffken is the Chief Financial Officer of the Issuer. Julian Adams c/o Elicio, One Kendall Sq. Bldg. 1400 West, Suite 14303 Cambridge MA MASSACHUSETTS 02139 Director Executive Officer Mr. Adams is the Executive Chairman of the Board of Directors of the Issuer. Isaac Kohlberg c/o Elicio, One Kendall Sq. Bldg. 1400 West, Suite 14303 Cambridge MA MASSACHUSETTS 02139 Director Frank Haluska c/o Elicio, One Kendall Sq. Bldg. 1400 West, Suite 14303 Cambridge MA MASSACHUSETTS 02139 Director Robert Ruffolo c/o Elicio, One Kendall Sq. Bldg. Building 1400 West, Suite 14303 Cambridge MA MASSACHUSETTS 02139 Director Robert Connelly c/o Elicio, One Kendall Sq. Bldg. Building 1400 West, Suite 14303 Cambridge MA MASSACHUSETTS 02139 Executive Officer Director Mr. Connelly is the Chief Executive Officer of the Issuer. Biotechnology Decline to Disclose 06b false 2019-09-30 false true true true Series B Preferred Stock and Warrants. false 0 None None Maxim Merchant Capital 120708 405 LEXINGTON AVENUE New York NY NEW YORK 10174 All States false 7000000 7000000 0 false 2 700000 0 The persons named in Item 12 may receive a commission from the gross proceeds of the offering. 0 false Elicio Therapeutics, Inc. /s/ Robert Connelly Robert Connelly Chief Executive Officer of the Issuer 2019-10-14